[104 Pages Report] MarketsandMarkets forecasts the wearable injectors market is estimated to grow from USD 5.57 billion in 2018 to USD 9.41 billion by 2023, at a compounded annual growth rate (CAGR) of 11.1% during the forecast period. Growth in the wearable injectors market is mainly driven by factors such as the rising prevalence of chronic diseases such as cancer, diabetes, and CVD; favorable reimbursement scenario in major markets; and technological advancements in injector devices. The objective of the report is to define, describe, and forecast the wearable injectors market size based on type, therapy, technology, end user and region.
Based on type, the market is segmented into on-body and off-body injectors. The on-body segment is expected to account for the largest share of the global wearable injectors market, by type. However, in the coming years the off-body injectors to witness the highest growth during the forecast period, The drawbacks associated with on-body wearable injectors, such as painful removal, skin sensitivity issues and irritation, and adhesive fitting issues have resulted in the increased adoption of off-body injectors.
Based on therapy, the wearable injectors market is segmented into immuno-oncology, diabetes, cardiovascular diseases, and other therapies. In 2018, the immuno-oncology segment is expected to account for the largest share of the wearable injectors market. The large share of this segment is mainly attributed to the high prevalence of cancer across the globe.
The North American region is leading the global wearable injectors market is expected to account for the largest share of the market in 2018. Moreover, North America is estimated to grow at the highest rate during the forecast period. Factors such as the rising prevalence of chronic diseases, favorable reimbursement scenario, and the presence of major market players in the region are expected to support the growth of the North American wearable injectors market.
North America is a major market for wearable injectors, boasting both large demand and a strong base/presence of players. In addition, the US and Canada both feature a favorable reimbursement scenario for wearable injectors, which has served to boost their uptake.
In the US, wearable injectors such as Neulasta and disposable insulin devices are covered on a co-payment basis by most insurance plans, including Medicare Part D. These co-payments and preferred statuses vary based on the plan. In addition, savings allied with a preferred brand are different. In Canada, the coverage for wearable insulin pumps varies across provinces, with a majority of provinces providing full reimbursement for these devices. For instance, the Assistive Device Program (ADP) reimburses 100% of the cost of insulin pump therapy in Canada.
A favorable reimbursement environment directly serves to boost the use of wearable injectors in these countries. Given North America’s large share in the market, this will reinforce market growth as a whole.
The traditional injectable route is an invasive and painful mode of drug delivery owing to which patients and care providers are increasingly focusing on alternative routes, such as oral, topical, and nasal routes. The oral route is the most preferred as it is easy to use, convenient, cost-effective, safe, and acceptable. Moreover, the introduction of needle-free drug delivery devices such as jet injectors also restricts the growth of the wearable injectors market.
Needle-free devices also come with an added advantage-they do not induce needle anxiety, which is a significant deterrent to the greater adoption of injectable drug treatments. Non-compliance among children as well as adults is mostly attributed to the pain associated with daily injections and the requirements of long-term therapy. According to a survey by the American Association of Diabetes Educators, as many as one-fifth to one-third of diabetics are hesitant or unwilling to inject themselves due to needle anxiety.
This directly affects the adoption of wearable injectors, and, as a result, serves to restrain market growth.
A growing focus on the use of biologics and mAbs to treat diseases such as rheumatoid arthritis, cardiovascular disease, and cancer will provide significant growth opportunities for wearable injectors, as these drugs need to be administered via the parenteral route (intravenous, subcutaneous, or intramuscular delivery). According to PhRMA (Pharmaceutical Research and Manufacturers of America), as many as 907 biologics are in development; it can be expected that the coming years will register significant growth in R&D activity in this sector.
Their efficacy in self-administration and convenience is likely to make wearable injectors prominent options for the delivery of such drugs.
A number of developing countries do not offer reimbursement for wearable injectors. For instance, in India, wearable insulin pumps are not reimbursed, and no specific guidelines regarding their use are given on prescription. In China, patients with Type 1 diabetes have to bear the entire cost of insulin pumps and supplies out-of-pocket. The lack of reimbursement directly affects access to and the adoption of wearable injectors and is thus expected to negatively impact the growth of the market in the coming years.
Report Metric |
Details |
Market size available for years |
2016–2023 |
Base year considered |
2017 |
Forecast period |
2018–2023 |
Forecast units |
Million (USD) |
Segments covered |
Type (On-body injectors and off-body injectors), Therapy (Immuno-oncology, diabetes, cardiovascular, and other therapies) and Region |
Geographies covered |
North America, Europe, APAC, and Rest of the World |
Companies covered |
Amgen (US), Medtronic (Ireland), Insulet Corporation (US), Tandem Diabetes Care (US), United Therapeutic Corporation (US), Valeritas (US), SteadyMed Therapeutics (US), Ypsomed (Switzerland), Becton, Dickinson and Company (US), Enable Injections (US), Sensile Medicals (Switzerland), and Bespak (UK). |
The research report categorizes the wearable injectors to forecast the revenues and analyze the trends in each of the following sub-segments:
The major market players in the wearable injectors market include Amgen (US), Medtronic (Ireland), Insulet Corporation (US), Tandem Diabetes Care (US), United Therapeutic Corporation (US), Valeritas (US), SteadyMed Therapeutics (US), Ypsomed (Switzerland), Becton, Dickinson and Company (US), Enable Injections (US), Sensile Medicals (Switzerland), and Bespak (UK)
In 2017, Amgen held the leading position in the global wearable injectors market. In 2017, the company accounted for a market share of 100% in the wearable injectors market for immuno-oncology. The company offers wearable injectors for the treatment of neutropenia in cancer patients under the brand-Neulasta Onpro On-body Injector.
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction
1.1 Objectives of Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.2.1 Key Data From Primary Sources
2.2.2.2 Key Industry Insights
2.3 Market Size Estimation Methodology
2.4 Market Data Validation and Triangulation
2.5 Assumptions for the Study
3 Executive Summary
4 Premium Insights
4.1 Wearable Injectors Market: Overview
4.2 Global Market, By Type, 2018 vs 2023
4.3 Geographic Analysis: Global Market, By Therapy
4.4 Geographic Snapshot: Global Market
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Prevalence of Chronic Diseases
5.2.1.2 Favorable Reimbursement Scenario in Major Markets
5.2.1.3 Technological Advancements and Design Development
5.2.2 Restraints
5.2.2.1 Preference for Alternative Drug Delivery Modes
5.2.3 Opportunities
5.2.3.1 Increasing Demand for Biologics and MABS
5.2.4 Challenges
5.2.4.1 Unfavorable Reimbursement Structure in Developing Countries
6 Wearable Injectors Market, By Type
6.1 Introduction
6.2 On-Body Injectors
6.3 Off-Body Injectors
7 Wearable Injectors Market, By Technology
7.1 Introduction
7.2 Spring-Based
7.3 Motor Driven
7.4 Rotary Pump
7.5 Expanding Battery
7.6 Other Technologies
8 Wearable Injectors Market, By Therapy
8.1 Introduction
8.2 Immuno-Oncology
8.3 Diabetes
8.4 Cardiovascular Diseases
8.5 Other Therapies
9 Wearable Injectors Market, By End User
9.1 Introduction
9.2 Hospitals
9.3 Clinics
9.4 Home Care Settings
9.5 Other End Users
10 Wearable Injectors Market, By Region
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Rest Of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Roapac
10.5 Rest Of The World
10.5.1 Latin America
10.5.2 Middle East And Africa
11 Competitive Landscape
11.1 Overview
11.2 Market Share Analysis, By Therapy
11.2.1 Immuno-Oncology
11.2.2 Diabetes
11.2.3 Cardiovascular Diseases
11.3 Competitive Scenario
11.3.1 Product Launches And Approvals
11.3.2 Expansions
11.3.3 Agreements, Collaborations, and Partnerships
12 Company Profiles
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 Amgen
12.2 Medtronic Plc
12.3 Insulet Corporation
12.4 Ypsomed
12.5 Becton, Dickinson And Company
12.6 Tandem Diabetes Care, Inc.
12.7 United Therapeutics Corporation
12.8 Valeritas, Inc.
12.9 Enable Injections
12.1 Steadymed Therapeutics
12.11 Johnson & Johnson
12.12 F. Hoffmann-La Roche Ltd.
12.13 West Pharmaceuticals
12.14 Unilife Corporation
12.15 Elcam
12.16 Valeritas, Inc.
12.17 Debiotech, Inc.
12.18 Cellnovo
12.19 Sonceboz
12.20 Neuma
*Details On Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.
13 Appendix
13.1 Discussion Guide
13.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.3 Available Customizations
13.4 Related Reports
13.5 Author Details
List of Tables (94 Tables)
Table 1 Wearable Injectors Market, By Type, 2016–2023 (USD Billion)
Table 2 On-Body Wearable Injectors Market, By Country, 2016–2023 (USD Million)
Table 3 Off-Body Wearable Injectors Market, By Country, 2016–2023 (USD Million)
Table 4 Wearable Injectors Market, By Therapy, 2016–2023 (USD Billion)
Table 5 Wearable Injectors Market for Immuno-Oncology, By Country, 2016–2023 (USD Million)
Table 6 Insulin Devices Available for Diabetic Patients
Table 7 Wearable Injectors Market for Diabetes, By Country, 2016–2023 (USD Million)
Table 8 Wearable Injectors Market for Cardiovascular Diseases, By Country, 2016–2023 (USD Million)
Table 9 Wearable Injectors Market for Other Therapies, By Country, 2016–2023 (USD Million)
Table 10 Wearable Injectors Market, By Technology, 2016-2023 (USD Billion)
Table 11 Wearable Injectors Market for Spring-Based, By Country, 2016–2023 (USD Million)
Table 12 Wearable Injectors Market for Motor-Driven, By Country, 2016–2023 (USD Million)
Table 13 Wearable Injectors Market for Rotary Pump, By Country, 2016–2023 (USD Million)
Table 14 Wearable Injectors Market for Expanding Battery, By Country, 2016–2023 (USD Million)
Table 15 Wearable Injectors Market for Other Technologies, By Country, 2016–2023 (USD Million)
Table 16 Wearable Injectors Market, By End User, 2016-2023 (USD Billion)
Table 17 Wearable Injectors Market for Hospital, By Country, 2016–2023 (USD Million)
Table 18 Wearable Injectors Market for Clinic, By Country, 2016–2023 (USD Million)
Table 19 Wearable Injectors Market for Home Care, By Country, 2016–2023 (USD Million)
Table 20 Wearable Injectors Market for Other End User, By Country,2016–2023 (USD Million)
Table 21 Wearable Injectors Market, By Region, 2016-2023 (USD Million)
Table 22 North America: Wearable Injectors Market, By Country, 2016-2023 (USD Million)
Table 23 North America: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 24 North America: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 25 North America: Wearable Injectors Market, By Technology, 2016-2023 (USD Million)
Table 26 North America: Wearable Injectors Market, By End User, 2016-2023 (USD Million)
Table 27 US: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 28 US: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 29 US: Wearable Injectors Market, By Technology, 2016-2023 (USD Million)
Table 30 US: Wearable Injectors Market, By End User, 2016-2023 (USD Million)
Table 31 Canada: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 32 Canada: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 33 Canada: Wearable Injectors Market, By Technology, 2016-2023 (USD Million)
Table 34 Canada: Wearable Injectors Market, By End User, 2016-2023 (USD Million)
Table 35 Recent Developments in the Wearable Injectors Market in Europe, 2015–2018
Table 36 Europe: Wearable Injectors Market, By Country, 2016-2023 (USD Million)
Table 37 Europe: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 38 Europe: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 39 Europe: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 40 Europe: Wearable Injectors Market, By Technology, 2016-2023 (USD Million)
Table 41 Europe: Wearable Injectors Market, By End User, 2016-2023 (USD Million)
Table 42 Germany: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 43 Germany: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 44 Germany: Wearable Injectors Market, By Technology, 2016-2023 (USD Million)
Table 45 Germany: Wearable Injectors Market, By End User, 2016-2023 (USD Million)
Table 46 UK: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 47 UK: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 48 UK: Wearable Injectors Market, By Technology, 2016-2023 (USD Million)
Table 49 UK: Wearable Injectors Market, By End User, 2016-2023 (USD Million)
Table 50 France: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 51 France: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 52 France: Wearable Injectors Market, By Technology, 2016-2023 (USD Million)
Table 53 France: Wearable Injectors Market, By End User, 2016-2023 (USD Million)
Table 54 RoE: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 55 RoE: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 56 RoE: Wearable Injectors Market, By Technology, 2016-2023 (USD Million)
Table 57 RoE: Wearable Injectors Market, By End User, 2016-2023 (USD Million)
Table 58 Asia Pacific: Wearable Injectors Market, By Country, 2016-2023 (USD Million)
Table 59 Asia Pacific: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 60 Asia Pacific: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 61 Asia Pacific: Wearable Injectors Market, By Technology, 2016-2023 (USD Million)
Table 62 Asia Pacific: Wearable Injectors Market, By End User, 2016-2023 (USD Million)
Table 63 Japan: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 64 Japan: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 65 Japan: Wearable Injectors Market, By Technology, 2016-2023 (USD Million)
Table 66 Japan: Wearable Injectors Market, By End User, 2016-2023 (USD Million)
Table 67 China: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 68 China: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 69 China: Wearable Injectors Market, By Technology, 2016-2023 (USD Million)
Table 70 China: Wearable Injectors Market, By End User, 2016-2023 (USD Million)
Table 71 India: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 72 India: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 73 India: Wearable Injectors Market, By Technology, 2016-2023 (USD Million)
Table 74 India: Wearable Injectors Market, By End User, 2016-2023 (USD Million)
Table 75 RoAPAC: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 76 RoAPAC: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 77 RoAPAC: Wearable Injectors Market, By Technology, 2016-2023 (USD Million)
Table 78 RoAPAC: Wearable Injectors Market, By End User, 2016-2023 (USD Million)
Table 79 Conferences in Africa, Brazil, and the Middle East (2016–2018)
Table 80 RoW: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 81 RoW: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 82 RoW: Wearable Injectors Market, By Technology, 2016-2023 (USD Million)
Table 83 RoW: Wearable Injectors Market, By End User, 2016-2023 (USD Million)
Table 84 Latin America: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 85 Latin America: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 86 Latin America: Wearable Injectors Market, By Technology, 2016-2023 (USD Million)
Table 87 Latin America: Wearable Injectors Market, By End User, 2016-2023 (USD Million)
Table 88 Middle East & Africa: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 89 Middle East & Africa: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 90 Middle East & Africa: Wearable Injectors Market, By Technology, 2016-2023 (USD Million)
Table 91 Middle East & Africa: Wearable Injectors Market, By End User, 2016-2023 (USD Million)
Table 92 Product Launches and Approvals
Table 93 Expansions
Table 94 Agreements, Collaborations, and Partnerships
List of Figures (30 Figures)
Figure 1 Wearable Injectors Market: Research Methodology Steps
Figure 2 Break Down of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Research Design
Figure 6 Data Triangulation Methodology
Figure 7 Immuno-Oncology Therapy Segment to Dominate the Wearable Injectors Market in 2018
Figure 8 On-Body Injectors to Account for the Largest Share of the Global Market in 2018
Figure 9 North America to Witness the Highest Market Growth During the Forecast Period
Figure 10 Growing Prevalence of Chronic Diseases is Driving Market Growth
Figure 11 On-Body Injectors Segment to Dominate the Market in 2018
Figure 12 Immuno-Oncology Segment to Command the Largest Share of the Market in 2018
Figure 13 North America to Witness the Highest Growth Rate During the Forecast Period
Figure 14 Wearable Injectors Market: Drivers, Restraints, Opportunities, & Challenges
Figure 15 Global Market, By Type, 2018 vs 2023 (USD Billion)
Figure 16 Wearable Injectors Market, By Therapy, 2018 vs 2023 (USD Billion)
Figure 17 North America to Command the Largest Market Share in 2018
Figure 18 North America: Market Snapshot
Figure 19 Europe: Market Snapshot
Figure 20 Asia Pacific: Market Snapshot
Figure 21 RoW: Market Snapshot
Figure 22 Strategies Adopted By Market Players (2014–2018)
Figure 23 Amgen: Company Snapshot (2017)
Figure 24 Medtronic PLC: Company Snapshot (2017)
Figure 25 Insulet Corporation: Company Snapshot (2017)
Figure 26 Ypsomed: Company Snapshot (2017)
Figure 27 BD: Company Snapshot (2017)
Figure 28 Tandem Diabetes Care: Company Snapshot (2017)
Figure 29 United Therapeutics Corporation: Company Snapshot (2017)
Figure 30 Valeritas: Company Snapshot (2017)
Benchmarking the rapid strategy shifts of the Top 100 companies in the Wearable Injectors Market
Request For Special Pricing
Growth opportunities and latent adjacency in Wearable Injectors Market